MCID: CHR418
MIFTS: 46

Chronic Leukemia

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Chronic Leukemia

MalaCards integrated aliases for Chronic Leukemia:

Name: Chronic Leukemia 12 51 14 69
Adult Chronic Leukemia 12
Cll 12
Cml 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1036
NCIt 46 C3483
UMLS 69 C1279296

Summaries for Chronic Leukemia

Disease Ontology : 12 A leukemia that develops slowly.

MalaCards based summary : Chronic Leukemia, also known as adult chronic leukemia, is related to leukemia, acute myeloid and chronic myelomonocytic leukemia. An important gene associated with Chronic Leukemia is WT1 (Wilms Tumor 1), and among its related pathways/superpathways are Development IGF-1 receptor signaling and Pathways in cancer. The drugs Arzerra and Campath have been mentioned in the context of this disorder. Affiliated tissues include b cells, myeloid and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is... more...

Related Diseases for Chronic Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Chronic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 28.5 BCR STAT5B WT1
2 chronic myelomonocytic leukemia 11.5
3 leukemia 11.2
4 leukemia, chronic lymphocytic 11.1
5 leukemia, t-cell, chronic 10.9
6 juvenile myelomonocytic leukemia 10.8
7 chronic neutrophilic leukemia 10.8
8 subacute leukemia 10.8
9 childhood leukemia 10.8
10 gastric ulcer 10.1 HGF PTGS2
11 female reproductive endometrioid cancer 10.1 PTEN WT1
12 ovarian epithelial cancer 10.0 BIRC5 PTGS2
13 keratocystic odontogenic tumor 9.9 BIRC5 PTGS2
14 ovarian serous carcinoma 9.9 PTGS2 WT1
15 bladder squamous cell carcinoma 9.7 HGF PTEN PTGS2
16 lung cancer susceptibility 3 9.7 BIRC5 HGF PTGS2
17 myelodysplastic syndrome 9.7
18 myeloma, multiple 9.6
19 lymphoma 9.6
20 disseminated intravascular coagulation 9.6
21 myeloid leukemia 9.6
22 hematologic cancer 9.6 BCR STAT5B WT1
23 leukemia, chronic myeloid 9.6 BCR STAT5B WT1
24 juvenile polyposis syndrome 9.6 PTEN PTGS2
25 b-cell growth factor 9.4
26 leukemia, chronic lymphocytic 2 9.4
27 myelofibrosis 9.4
28 wilms tumor 5 9.4
29 human herpesvirus 8 9.4
30 glucocorticoid resistance, generalized 9.4
31 b-cell expansion with nfkb and t-cell anergy 9.4
32 wilms tumor 6 9.4
33 parotitis 9.4
34 prostatitis 9.4
35 lymphadenitis 9.4
36 richter's syndrome 9.4
37 myeloproliferative neoplasm 9.4
38 pneumonia 9.4
39 herpes zoster 9.4
40 leukemia, b-cell, chronic 9.4
41 endotheliitis 9.4

Comorbidity relations with Chronic Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Chronic Leukemia:



Diseases related to Chronic Leukemia

Symptoms & Phenotypes for Chronic Leukemia

GenomeRNAi Phenotypes related to Chronic Leukemia according to GeneCards Suite gene sharing:

25 (show all 28)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 STAT5B WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.84 STAT5B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.84 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.84 STAT5B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.84 STAT5B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.84 BIRC5
7 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.84 BIRC5
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PTEN
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 WT1 PTEN
10 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.84 BIRC5
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.84 PTEN
12 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 PTEN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.84 STAT5B
14 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.84 BIRC5
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.84 PTEN STAT5B WT1 BIRC5
16 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.84 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.84 BIRC5 STAT5B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.84 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 PTEN
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.84 WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.84 STAT5B
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.84 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.84 STAT5B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 PTEN
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 PTEN
28 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 PTEN WT1

MGI Mouse Phenotypes related to Chronic Leukemia:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 STAT5B WT1 BIRC5 PTGS2 GFI1B HGF
2 hematopoietic system MP:0005397 10.1 STAT5B WT1 SOAT1 PTGS2 GFI1B HGF
3 cardiovascular system MP:0005385 10.04 SOAT1 WT1 PTGS2 GFI1B HGF ABCB4
4 homeostasis/metabolism MP:0005376 10.02 SOAT1 STAT5B WT1 BIRC5 PTGS2 GFI1B
5 endocrine/exocrine gland MP:0005379 9.98 SOAT1 STAT5B WT1 BIRC5 PTGS2 ABCB4
6 immune system MP:0005387 9.97 STAT5B WT1 SOAT1 BIRC5 PTGS2 GFI1B
7 embryo MP:0005380 9.93 WT1 BIRC5 PTGS2 GFI1B HGF PTEN
8 liver/biliary system MP:0005370 9.86 STAT5B WT1 PTGS2 SOAT1 HGF ABCB4
9 neoplasm MP:0002006 9.55 SOAT1 WT1 PTGS2 ABCB4 PTEN
10 normal MP:0002873 9.43 STAT5B WT1 BIRC5 PTGS2 BCR PTEN
11 renal/urinary system MP:0005367 9.02 STAT5B WT1 PTGS2 BCR PTEN

Drugs & Therapeutics for Chronic Leukemia

FDA approved drugs:

(show all 7)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arzerra 17 45 OFATUMUMAB GlaxoSmithKline October 2009
2
Campath 17 45 ALEMTUZUMAB Berlex Laboratories May 2001
3
Imbruvica 17 45 IBRUTINIB Pharmacyclics November of 2013/February 2014
4
Revlimid 17 45 LENALIDOMIDE Celgene June 2013
5
Rituxan 17 45 RITUXIMAB Biogen IDEC, Genentech November 1997
6
Treanda 17 45 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
7
Zydelig 17 45 IDELALISIB Gilead July 2014

Drugs for Chronic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1
4 Antiviral Agents Phase 4,Phase 2,Phase 1
5 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1
6 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
7 Anti-HIV Agents Phase 4
8 Anti-Retroviral Agents Phase 4
9 JM 3100 Phase 4
10 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Imatinib Mesylate Phase 4,Phase 3,Phase 2 123596
12 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
13
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
14
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
15
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
17
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1 104987-11-3 445643 439492
18
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
19
alemtuzumab Approved, Investigational Phase 3,Phase 2 216503-57-0
20
Chlorambucil Approved Phase 3 305-03-3 2708
21
Dasatinib Approved, Investigational Phase 3,Phase 1,Phase 2 302962-49-8 3062316
22 Antimetabolites Phase 2, Phase 3,Phase 1
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
24 Antiemetics Phase 2, Phase 3
25 Anti-Inflammatory Agents Phase 2, Phase 3
26 Antilymphocyte Serum Phase 2, Phase 3
27 Antineoplastic Agents, Hormonal Phase 2, Phase 3
28 Autonomic Agents Phase 2, Phase 3
29 Calcineurin Inhibitors Phase 2, Phase 3,Phase 1
30 Gastrointestinal Agents Phase 2, Phase 3
31 glucocorticoids Phase 2, Phase 3
32 Hormone Antagonists Phase 2, Phase 3
33 Hormones Phase 2, Phase 3
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
35 Methylprednisolone acetate Phase 2, Phase 3
36 Methylprednisolone Hemisuccinate Phase 2, Phase 3
37 Neuroprotective Agents Phase 2, Phase 3
38 Peripheral Nervous System Agents Phase 2, Phase 3
39 Prednisolone acetate Phase 2, Phase 3
40 Prednisolone hemisuccinate Phase 2, Phase 3
41 Prednisolone phosphate Phase 2, Phase 3
42 Protective Agents Phase 2, Phase 3,Phase 1
43 tyrosine Nutraceutical Phase 3
44
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
45
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
46
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
47
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
48
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
49 Thiotepa Approved, Investigational Phase 2 52-24-4 5453
50 Mirabegron Approved Phase 2 223673-61-8

Interventional clinical trials:

(show top 50) (show all 55)

# Name Status NCT ID Phase Drugs
1 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor Completed NCT01362985 Phase 4
2 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
3 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
4 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
5 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
6 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
7 Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Completed NCT01511289 Phase 3 Imatinib;Radotinib
8 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
9 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
10 Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia Recruiting NCT03079505 Phase 3 Dasatinib 100 MG [Sprycel];Nilotinib 150mg oral capsule [Tasigna]
11 A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Active, not recruiting NCT00471497 Phase 3 nilotinib;imatinib
12 Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. Terminated NCT02108951 Phase 3 Nilotinib
13 Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Terminated NCT00519090 Phase 3 Imatinib;Nilotinib (AMN107)
14 Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Unknown status NCT01472055 Phase 2 Fludarabine
15 Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) Completed NCT00042016 Phase 2 decitabine (5-aza-2'deoxycytidine)
16 Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Completed NCT00002502 Phase 2 busulfan;cyclophosphamide;cytarabine
17 Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) Completed NCT01218477 Phase 1, Phase 2 Dasatinib;BMS-833923
18 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Completed NCT00378534 Phase 2 Fludarabine;Cyclosporine;Cyclophosphamide
19 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
20 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2 Mirabegron
21 Stem Cell Transplantation for Patients With Cancers of the Blood Completed NCT00467961 Phase 2
22 Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation Completed NCT00859586 Phase 2
23 Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Completed NCT00074490 Phase 2 Rituximab;Fludarabine;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Filgrastim
24 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies Completed NCT00079391 Phase 2
25 A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00073489 Phase 2 OSI-461
26 Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00230282 Phase 2 Alemtuzumab;Fludarabine;Cytoxan
27 Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Completed NCT01336712 Phase 2
28 Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT01191190 Phase 2 Ofatumumab/HDMP
29 A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia Completed NCT00431873 Phase 2 MGCD0103
30 Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy Recruiting NCT01521611 Phase 1, Phase 2
31 Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Recruiting NCT02169791 Phase 2 MLN9708
32 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
33 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Recruiting NCT01203722 Phase 1, Phase 2
34 Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR- Recruiting NCT02885766 Phase 1, Phase 2 PF-114
35 Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT Terminated NCT01220297 Phase 2 Sirolimus;Mycophenolate mofetil (MMF);Carmustine;Etoposide;Cyclophosphamide (Cyclo, CY);FTBI
36 Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells Terminated NCT01624701 Phase 1, Phase 2
37 Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) Terminated NCT00185523 Phase 2
38 A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) Terminated NCT00076401 Phase 2 Motexafin gadolinium
39 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome Completed NCT00077558 Phase 1 fludarabine phosphate;triapine
40 Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer Completed NCT00005785 Phase 1 GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
41 Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Completed NCT00273936 Phase 1 AVN-944 capsules for oral administration
42 Umbilical Cord Blood Transplantation From Unrelated Donors Recruiting NCT03016806 Phase 1 Cyclophosphamide;Mesna;Busulfan;Fludarabine;Melphalan
43 A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia Terminated NCT00587457 Phase 1 CAT-8015 5 mcg/kg;CAT-8015 10 mcg/kg;CAT-8015 20 mcg/kg
44 Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias Completed NCT01144793
45 Fungemia in Hematologic Malignancies Completed NCT02451592
46 Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia Completed NCT02520895
47 Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log Recruiting NCT03239886
48 Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor Recruiting NCT02842333
49 Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes Recruiting NCT02560883
50 Stem Cell Transplant for Hematological Malignancy Recruiting NCT00176930 Cyclophosphamide;Busulfan

Search NIH Clinical Center for Chronic Leukemia

Genetic Tests for Chronic Leukemia

Anatomical Context for Chronic Leukemia

MalaCards organs/tissues related to Chronic Leukemia:

38
B Cells, Myeloid, Bone Marrow, Bone, T Cells, Monocytes, Nk Cells

Publications for Chronic Leukemia

Articles related to Chronic Leukemia:

(show all 50)
# Title Authors Year
1
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. ( 27229716 )
2016
2
Your patient has chronic leukemia: Now what? ( 27505878 )
2016
3
Correlation of Cadmium and Magnesium in the Blood and Serum Samples of Smokers and Non-Smokers Chronic Leukemia Patients. ( 27511371 )
2016
4
Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico. ( 27557388 )
2016
5
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country. ( 27123350 )
2016
6
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. ( 27579615 )
2016
7
Antileukemic Effect of Tualang Honey on Acute and Chronic Leukemia Cell Lines. ( 26613081 )
2015
8
Organizing pneumonia appearing in B-cell chronic leukemia malignancy progression - a case report. ( 25985790 )
2015
9
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma. ( 26295844 )
2015
10
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. ( 26107113 )
2015
11
Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome. ( 24811835 )
2014
12
Analysis of the erythroid differentiation effect of flavonoid apigenin on K562 human chronic leukemia cells. ( 25058688 )
2014
13
Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy. ( 23936692 )
2013
14
Chronic leukemia. ( 24267282 )
2013
15
Exaggerated insect bite reaction related to chronic leukemia. ( 23541024 )
2013
16
Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/I^-catenin function. ( 22708678 )
2012
17
Incidental diagnosis of a retroperitoneal schwannoma in a patient with chronic leukemia undergoing prostatic biopsy. ( 22760935 )
2012
18
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. ( 22547610 )
2012
19
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( 22585692 )
2012
20
[Regulation of wild type PTEN gene on Survivin, Xiap and Smac in chronic leukemia cells]. ( 22333553 )
2011
21
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. ( 21678379 )
2011
22
Understanding and Targeting the Wnt/I^-Catenin Signaling Pathway in Chronic Leukemia. ( 23213540 )
2011
23
Prevalence of human herpesvirus 8 DNA in peripheral blood mononuclear cells of acute and chronic leukemia patients in Taiwan. ( 21392127 )
2011
24
[Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]. ( 20352702 )
2010
25
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. ( 19633691 )
2010
26
Inhibition of cell growth by Stellera chamaejasme extract is associated with induction of autophagy and differentiation in chronic leukemia K562 cells. ( 20547324 )
2010
27
Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation-dependent probe amplification in chronic leukemia. ( 21049055 )
2010
28
Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients. ( 20376582 )
2010
29
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( 19812383 )
2009
30
[Treatment of myeloproliferative neoplasms other than chronic leukemia]. ( 19860198 )
2009
31
Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. ( 19360458 )
2009
32
How I treat acute and chronic leukemia in pregnancy. ( 18472198 )
2008
33
Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. ( 18773885 )
2008
34
[Expression of cyclooxygenase-2 in bone marrow cells of chronic leukemia and its significance]. ( 17956662 )
2007
35
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). ( 17611571 )
2007
36
PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. ( 16914202 )
2007
37
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. ( 17041886 )
2006
38
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. ( 16019534 )
2005
39
Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study. ( 16084950 )
2005
40
TNR/11q#1 trinucleotide (GCC)n repeat alleles and predisposition to acute and chronic leukemia. ( 15225161 )
2004
41
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. ( 12007503 )
2002
42
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. ( 10979972 )
2000
43
Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. ( 10676644 )
2000
44
Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. ( 9150348 )
1997
45
MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. ( 8656699 )
1996
46
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. ( 7911548 )
1994
47
Interferon DNA polymorphism in chronic leukemia. ( 7912973 )
1994
48
A combination of lipopolysaccharide and B-cell growth factor increases lymphocyte metaphase yields in B-cell chronic leukemia. ( 8500104 )
1993
49
Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. ( 1972761 )
1990
50
Herpes zoster with a varicelliform eruption and parotitis in chronic leukemia. ( 14794487 )
1951

Variations for Chronic Leukemia

Expression for Chronic Leukemia

Search GEO for disease gene expression data for Chronic Leukemia.

Pathways for Chronic Leukemia

GO Terms for Chronic Leukemia

Biological processes related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.76 ABCB4 PTEN PTGS2 SOAT1
2 response to lipopolysaccharide GO:0032496 9.65 ABCB4 BCR PTGS2
3 positive regulation of cell proliferation GO:0008284 9.65 BIRC5 HGF PTEN PTGS2 STAT5B
4 peptidyl-tyrosine phosphorylation GO:0018108 9.61 BCR HGF STAT5B
5 response to organic cyclic compound GO:0014070 9.54 ABCB4 PTEN PTGS2
6 lactation GO:0007595 9.51 ABCB4 STAT5B
7 response to organic substance GO:0010033 9.5 ABCB4 PTEN PTGS2
8 platelet-derived growth factor receptor signaling pathway GO:0048008 9.49 BCR PTEN
9 response to vitamin D GO:0033280 9.4 ABCB4 PTGS2
10 response to estradiol GO:0032355 9.26 ABCB4 PTEN PTGS2 STAT5B
11 maintenance of permeability of blood-brain barrier GO:0035633 9.16 ABCB4 PTGS2
12 negative regulation of apoptotic process GO:0043066 9.1 BIRC5 HGF PTEN PTGS2 STAT5B WT1

Molecular functions related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.7 ABCB4 ARL11 BCR BIRC5 GFI1B HGF
2 protein tyrosine kinase activity GO:0004713 9.33 BCR HGF STAT5B
3 enzyme binding GO:0019899 8.92 BCR BIRC5 PTEN PTGS2

Sources for Chronic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....